On May 15, 2014, AbbVie Inc (NYSE:ABBV), has named Michael Severino, M.D. its new Executive Vice President, Research and Development (R&D) and Chief Scientific Officer. Dr. Severino’s track record of innovation within the biotech industry aligns with AbbVie’s vision as a new biopharmaceutical leader with a rapidly emerging pipeline. AbbVie Inc (NYSE:ABBV), net profit margin is 21.80% and weekly performance is 1.28%. On last trading day company shares ended up $52.93. Analysts mean target price for the company is $54.68. AbbVie Inc (NYSE:ABBV), distance from 50-day simple moving average (SMA50) is 4.01%.
On May 13, 2014, Aerie Pharmaceuticals Inc (NASDAQ:AERI), announced that Richard Rubino, chief financial officer, will present at the UBS Global Healthcare Conference on Tuesday, May 20, 2014 at 3:30 pm Eastern Time in New York, NY. Mr. Rubino will provide an Aerie overview and business update. Aerie Pharmaceuticals Inc (NASDAQ:AERI), fell 0.13% in last trading session and ended the day on $15.33. AERI, return on assets is -10.3.70%. Aerie Pharmaceuticals Inc (NASDAQ:AERI), quarterly performance is -20.40%.
Intercept Pharmaceuticals Inc (NASDAQ:ICPT), issued its quarterly earnings data on Wednesday. The company reported ($1.59) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.72) by $0.87, Analyst Ratings Networkreports. Intercept Pharmaceuticals Inc (NASDAQ:ICPT), shares moved down 0.66% in last trading session and was closed at $280.26, while trading in range of $272.90 – 285.60. Intercept Pharmaceuticals Inc (NASDAQ:ICPT), year to date (YTD) performance is 310.46%.
On May 12, 2014, Alliqua Inc (NASDAQ:ALQA), a provider of advanced wound care products, announced financial results for the first quarter ended March 31, 2014. Revenues for the first quarter of 2014 were approximately $591,000, an increase of 51% compared to first quarter 2013 revenues of approximately $392,000. This increase was largely due to an increase in revenues of the Company’s proprietary and licensed products of approximately $106,000 compared to the first quarter of 2013. Also contributing to the increase was an increase in contract manufacturing revenue of approximately $93,000. Alliqua Inc (NASDAQ:ALQA), ended the last trading day at $6.64. Company weekly volatility is calculated as 3.79% and price to cash ratio as 8.64. Alliqua Inc (NASDAQ:ALQA), showed a positive weekly performance of 0.30%.
A newspaper controlled by Chinese legal officials leveled fresh accusations at GlaxoSmithKline plc (ADR) (NYSE:GSK), on Friday, just two days after police accused its former top China executive of orchestrating widespread corporate bribery to boost sales. GlaxoSmithKline plc (ADR) (NYSE:GSK), net profit margin is 27.70% and weekly performance is 1.97%. On last trading day company shares ended up $55.43. Analysts mean target price for the company is $60.33. GlaxoSmithKline plc (ADR) (NYSE:GSK), distance from 50-day simple moving average (SMA50) is 3.34%.